Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Baudoin, Maël
30  Ergebnisse:
Personensuche X
?
1

Cost-utility analysis of four WHO-recommended sofosbuvir-ba..:

Boyer, Sylvie ; Baudoin, Maël ; Nishimwe, Marie Libérée...
BMC Health Services Research.  22 (2022)  1 - p. , 2022
Link: https://doi.org/10.1186/..
 
?
2

Late presentation for HCV care: Time to target people with ..:

Santos, Melina ; Protopopescu, Camelia ; Delarocque‐Astagneau, Elizabeth...
Liver International.  42 (2021)  1 - p. 38-49 , 2021
Link: https://doi.org/10.1111/..
 
?
3

Effectiveness of direct‐acting antivirals for chronic hepat..:

Djaogol, Tchadine ; Fontaine, Hélène ; Baudoin, Maël...
Liver International.  41 (2021)  10 - p. 2328-2340 , 2021
Link: https://doi.org/10.1111/..
 
?
4

Individual and healthcare supply-related barriers to treatm..:

Coulaud, Pierre-Julien ; Protopopescu, Camélia ; Ndiaye, Khadim...
Health Policy and Planning.  36 (2020)  2 - p. 137-148 , 2020
Link: https://doi.org/10.1093/..
 
?
5

Long‐term clinical benefits of Sofosbuvir‐based direct anti..:

Baudoin, Mael ; Woode, Maame E. ; Nishimwe, Marie Libérée...
Liver International.  40 (2020)  11 - p. 2643-2654 , 2020
Link: https://doi.org/10.1111/..
 
?
6

Cost-utility analysis of four WHO-recommended sofosbuvir-ba..:

Boyer, Sylvie ; Baudoin, Maël ; Nishimwe, Marie Libérée...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897946/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
7

Cost-utility analysis of four WHO-recommended sofosbuvir-ba..:

Boyer, Sylvie ; Baudoin, Maël ; Nishimwe, Marie, Libérée...
info:eu-repo/semantics/altIdentifier/doi/10.1186/s12913-021-07289-0.  , 2022
Link: https://inserm.hal.scien..
 
?
8

Cost-utility analysis of four WHO-recommended sofosbuvir-ba..:

Boyer, Sylvie ; Baudoin, Maël ; Nishimwe, Marie, Libérée...
info:eu-repo/semantics/altIdentifier/doi/10.1186/s12913-021-07289-0.  , 2022
Link: https://inserm.hal.scien..
 
?
9

Cost-utility analysis of four WHO-recommended sofosbuvir-ba..:

Boyer, Sylvie ; Baudoin, Maël ; Nishimwe, Marie, Libérée...
info:eu-repo/semantics/altIdentifier/doi/10.1186/s12913-021-07289-0.  , 2022
Link: https://inserm.hal.scien..
 
?
10

Cost-utility analysis of four WHO-recommended sofosbuvir-ba..:

Boyer, Sylvie ; Baudoin, Maël ; Nishimwe, Marie Libérée...
Boyer , S , Baudoin , M , Nishimwe , M L , Santos , M , Lemoine , M , Maradan , G , Sylla , B , Kouanfack , C , Carrieri , P , Mourad , A , Rouveau , N , Moh , R , Seydi , M , Attia , A , Woode , M E & Lacombe , K 2022 , ' Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa ' , BMC Health Services Research , vol. 22 , no. 1 , 303 . https://doi.org/10.1186/s12913-021-07289-0.  , 2022
Link: https://research.monash...
 
?
11

Cost-utility analysis of four WHO-recommended sofosbuvir-ba..:

Boyer, Sylvie ; Baudoin, Maël ; Nishimwe, Marie, Libérée...
info:eu-repo/semantics/altIdentifier/doi/10.1186/s12913-021-07289-0.  , 2022
Link: https://inserm.hal.scien..
 
?
12

Effectiveness of direct‐acting antivirals for chronic hepat..:

Djaogol, Tchadine ; Fontaine, Hélène ; Baudoin, Maël...
info:eu-repo/semantics/altIdentifier/doi/10.1111/liv.14823.  , 2021
Link: https://inserm.hal.scien..
 
?
13

Effectiveness of direct‐acting antivirals for chronic hepat..:

Djaogol, Tchadine ; Fontaine, Hélène ; Baudoin, Maël...
info:eu-repo/semantics/altIdentifier/doi/10.1111/liv.14823.  , 2021
Link: https://inserm.hal.scien..
 
?
14

Individual and healthcare supply-related barriers to treatm..:

Coulaud, Pierre-Julien ; Protopopescu, Camelia ; Ndiaye, Khadim...
info:eu-repo/semantics/altIdentifier/doi/10.1093/heapol/czaa153.  , 2021
Link: https://hal.umontpellier..
 
?
15

Effectiveness of direct‐acting antivirals for chronic hepat..:

Djaogol, Tchadine ; Fontaine, Hélène ; Baudoin, Maël...
info:eu-repo/semantics/altIdentifier/doi/10.1111/liv.14823.  , 2021
Link: https://inserm.hal.scien..
 
1-15